Gastrointestinal Diseases

Group leader: Luis Bujanda, M.D., Ph.D.

Donostialdea IHO

Strategic Objectives

  • Gastrointestinal Oncology: Cancer is the primary cause of death in men and the second in women. Colorectal cancer (CRC) is the most common tumour as regards incidence and the second as regards mortality.
    • To determine which test is best for the early diagnosis of this disease and aspects to improve its acceptance and quality.
      • To compare the efficacy of screening using the immunological method of detecting faecal occult blood (FOB) with a colonoscopy in the intermediate risk population (asymptomatic individuals aged 50-69 years with no personal or family history of CRC) to detect CRC or advanced adenomas, in a first round of screening.
      • To assess new biochemical markers for the early diagnosis of colon cancer.
      • To assess the colonoscopy and FOB in first degree relatives of CRC.
    • To determine the genetic factors that foster its appearance, the response to treatment and the adverse effects of treatment (Epicolon I, Epicolon II, Epipolip, Epineo, Colonprev, Smarthealth and Epicolon III studies).
    • Search for new therapeutic targets in pancreatic cancer, cholangiocarcinoma, hepatocarcinoma and gastric cancer.
  • Other digestive diseases: Our objective is to continue to stand out as a group in the Helicobacter pylori pathology (diagnosis and treatment), in research into the secondary gastrointestinal effects produced by the anti-inflammatories, and in other areas, such as ischemic colitis or inflammatory bowel disease.

Main lines of research

  • Gastrointestinal Oncology.
    • Colon cancer (CRC) screening.
    • Molecular bases of hereditary and familial colorectal cancer. Diagnostic and therapeutic implications.
    • Pancreatic cancer.
    • Gastric cancer
  • Inflammatory Bowel Disease
    • To study the prevalence of hepatitis infection in patients with inflammatory bowel disease.
  • Gastrointestinal Diseases: Helicobacter Pylori and other diseases.
    • Treatment and evolution of patients with Helicobacter pylori infection.

Team Members

Name Surname
Center E-mail
Marc Clos García Donostialdea IHO
Jose María Enríquez Navascues Donostialdea IHO
Ines Gil Lasa Donostialdea IHO
Ana Goitia Viaña Donostialdea IHO
Elizabeth Hijona Muruamendiaraz Biodonostia HRI
Jacobo Lizasoain Urcola Donostialdea IHO
Laura Izquierdo Sánchez Biodonostia HRI

Scientific Output


Published: 10 / 182

Colonprev. Study Investigators, Spanish Gastroenterological Assoc. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening.

Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, Andreu M, Carballo F, Morillas JD, Hernandez C, Jover R, Montalvo I, Arenas J, Laredo E, Hernandez V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andres M, Teruel G, Peris A, Roncales MP, Polo-Tomas M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Perez-Riquelme, F, Alonso-Abreu I, De la Vega-Prieto M, Reyes-Melian JM, Cacho G, Diaz-Tasende J, Herreros de Tejada A, Poves C, Santander C, Gonzalez-Navarro A.

N. Engl. J. Med. 2012. 366: 697-706. FI: 53.298 (Q1).

Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis.

Westerlind H, Mellander MR, Bresso B, Munch A, Bonfiglio F, Assadi G, Rafter J, Hübenthal M, Lieb W, Källberg H, Brynedal B, Padyukov L, Halfvarson J, Törkvist L, Bjork J, Andreasson A, Agreus L, Almer S, Miehlke S, Madisch A, Ohlsson B, Löfberg R, Hultcrantz R, Franke A, D’Amato M.

Gut. 2015; Nov 2 [Epub ahead of print]. FI: 14.921 (Q1).

Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies.

Castells A, Bessa X, Quintero E, Bujanda L, Cubiella J, Salas D, Lanas A, Carballo F, Morillas JD, Hernandez C, Jover R, Montalvo I, Arenas J, Cosme A, Hernandez V, Iglesias B, Castro I, Cid L, Sala T, Ponce M, Andres M, Teruel G, Peris A, Roncales MP, Gonzalez-Rubio F, Seoane-Urgorri A, Grau J, Serradesanferm A, Pellise M, Ono A, Cruzado J, Perez-Riquelme F, Alonso-Abreu I, Carrillo-Palau M, de la Vega-Prieto M, Iglesias R, Amador J, Blanco JM, Sastre R, Ferrandiz J, Gonzalez-Hernandez MJ, Andreu M, COLONPREV Study Investigators.

JNCI. Natl. Cancer Inst. 2013; 105: 878-886. FI: 14.336 (Q1).

Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Urribarri AD, Munoz-Garrido P, Perugorria MJ, Erice O, Merino-Azpitarte M, Arbelaiz A, Lozano E, Hijona E, Jimenez-Agueero R, Fernandez-Barrena MG, Jimeno JP, Marzioni M, Marin JJG, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Banales JM.

Gut. 2014; 63: 1658-1667. FI: 13.319 (Q1).

Risk of cancer in cases of cuspected Lynch Syndrome without Germline Mutation.

Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, Zapater P, Castillejo A, Barbera VM, Juarez M, Bessa X, Xicola RM, Clofent J, Bujanda L, Balaguer F, Rene JM, de-Castro L, Marin-Gabriel JC, Lanas A, Cubiella J, Nicolas-Perez D, Brea-Fernandez A, Castellvi-Bel S, Alenda C, Ruiz-Ponte C, Carracedo A, Castells A, Andreu M, Llor X, Soto JL, Paya A, Jover R.

Gastroenterology. 2013; 144: 926-932. FI: 12.821 (Q1).

Expression of SLC22A1 Variants May Affect the Response of Hepatocellular Carcinoma and Cholangiocarcinoma to Sorafenib.

Herraez E, Lozano E, Macias RIR, Vaquero J, Bujanda L, Banales JM, Marin JJG, Briz O.

Hepatology. 2013; 58: 1065-1073. FI: 12.003 (Q1).

Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease.

Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, Gajdos G, Bedekovicsne C, Natasha B, Jason L, Ward CJ, Ritman EL, Kiyokawa H, LaRusso NF.

Gastroenterology 2012. 142: 622-310. FI: 11.675 (Q1).

Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis.

Banales JM, Saez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, Bogert PS. Tietz, Bujanda, Prieto L, Jesus M, Juan F., LaRusso NF.

Hepatology 2012. 56: 687-697. FI: 11.665 (Q1).

Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Munoz-Garrido P, Marin JJG, Perugorria MJ, Urribarri AD, Erice O, Saez E, Uriz M, Sarvide S, Portu AC, Axel R, Romero MR, Monte MJ, Santos-Laso A, Hijona E, Jimenez-Agueero R, Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JPH, Banales JM.

J. Hepatol. 2015; 63: 952-961. FI: 11.336 (Q1).

Altered underlying tubular function in HBV monoinfected patients receiving nucleos(t)ide analogs in a real-world setting: MENTE Study.

Rodriguez S, Garcia-Samaniego J, Prieto M, Calleja JL, Pascasio JM, Delgado MB, Crespo J, Buti M, Bonet L, Arenas JI, Fernandez CM, Sola R, Fraga E, Gonzalez-Dieguez L, Nunez O, Praga M, del Pino J, Romero-Gomez M, Morillas RM, Diago M, Castro A.

Hepatology. 2014; 60: 1097-0. FI: 11.190 (Q1).


Published: 10 / 14

Polycystic liver diseases: advanced insights into the molecular mechanisms.

Perugorria MJ, Masyuk TV, Marin JJ, Marzioni M, Bujanda L, LaRusso NF, Banales JM.

NAT REV GASTRO HEPAT. 2014; 11: 750-761. FI: 10.807 (Q1).

Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab.

Marín JJG, Sánchez de Medina F, Castaño B, Bujanda L, Romero MR, Martínez-Augustin O, Del Moral-Ávila R, Briz O.

Rev. 2012; 44: 148-172. FI: 6.400 (Q1).

Clinical relevance of KRAS mutations in codon 13: Where are we?

Er TK, Chen CC, Bujanda L, Herreros-Villanueva M.

Cancer Lett. 2014; 343: 1-5. FI: 5.016 (Q1).

MicroRNAs and cholestatic liver diseases.

Marin JJG, Bujanda L, Banales JM.

Curr. Opin. Gastroenterol. 2014; 30: 303-309. FI: 3.664 (Q1).

Molecular markers in pancreatic cancer diagnosis.

Herreros-Villanueva M, Gironella M, Castells A, Bujanda L.

Clin. Chim. Acta. 2013; 418: 22-29. FI: 2.850 (Q1).

KRAS mutations: Analytical considerations.

Herreros-Villanueva M, Chen C.C, Yuan, Shyng-Shiou F, Liu TC, Er Tze-Kiong.

Clin. Chim. Acta. 2014; 431: 211-220. FI: 2.764 (Q1).

Meta-analysis of randomized controlled trials comparing different techniques with primary closure for chronic pilonidal sinus.

Enriquez-Navascues JM, Emparanza JI, Alkorta M, Placer C.

TECH COLOPROCTOL. 2014; 18: 863-872. FI: 1.353 (Q3).

Pancreatic metastases due to renal carcinoma. Our cases and a literature review.

Markinez I, Jimenez R, Ruiz I, Villarreal E, Lizarazu A, Borda N, Arteaga X, Medrano MA, Guisasola E, Beguiristain A, Enriquez-Navascues JM.

Cir. Espan. 2013; 91: 90-95. FI: 0.871 (Q3).

Radiation proctitis and chronic and refractory bleeding. Experience with 4% formaldehyde.

Placer C, Lizarazu A, Borda N, Elosegui JL, Enriquez JM.

Cir. Espan. 2013; 91: 111-114. FI: 0.871 (Q3).

Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients.

Er TK, Chen CC, Bujanda L, Herreros-Villanueva M.

Biomed Res. Int. 2014; 591867. FI: 0.000 (Q4).


Published: 6 / 6

Spanish Soc Gastroenterology AEG, Spanish Soc Gastrointestinal Endos. Clinical practice Guidelines: quality of colonoscopy in colorectal cancer screening.

Jover R, Herraiz M, Alarcon O, Brullet E, Bujanda L, Bustamante M, Campo R, Carreno R, Castells A, Cubiella J, García-Iglesias P, Hervas AJ, Menchen P, Ono A, Panades A, Parra-Blanco A, Pellise M, Ponce M, Quintero E, Rene JM, Del Rio A, Sanchéz SA, Serradesanferm A, Izquierdo A, Soriano S, Vazquez E.

Endoscopy. 2012; 44: 444-451. FI: 5.210 (Q1).

Report from the Spanish Association of Coloproctology.

Biondo S, Enriquez-Navascues JM, Jimenez-Escovar F.

Colorectal Dis. 2015; 17: 374-0. FI: 2.351 (Q2).

Report from the Spanish Association of Coloproctology (AECP).

Biondo S, Enriquez-Navascues JM, Jimenez F.

COLORECTAL DIS. 2014; 16: 327-328. FI: 2.017 (Q2).

Perineal hernia following abdominoperineal amputation and myocutaneous flap.

Gallego L, Enriquez-Navascues JM, Saralegui Y.

Cir. Espan. 2013; 91: 534. FI: 0.871 (Q3).

Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer.

Herreros-Villanueva M, Bujanda L.

Annals Of Translational Medicine. 2016; 4: 64-64.

More insight into the diversity of cholangiocyte ciliopathies.

Perugorria MJ, Bujanda L, Banales JM.

Journal Of Hepatology. 2016; 65: 1083-1085. FI: 12,486 (Q1).


Published: 4 / 4

Risk of Upper and Lower Gastrointestinal Bleeding in Patients Taking Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, or Anticoagulants Reply.

Lanas A, Carrera P, Bujanda L, Garcia-Rodriguez LA.

Clin. Gastroenterol. Hepatol. 2015; 13: 2024-2025. FI: 7.896 (Q1).

Somatic second-hit mutations leads to polycystic liver diseases.

Banales JM, Munoz-Garrido P, Bujanda L.

World J. Gastroenterol. 2013; 19: 141-143. FI: 2.547 (Q2).

Alopecia areata in a patient receiving infliximab.

Ormaechea N, Lopez A, Munagorri-AI, Jaka A, Tuneu A.

Indian J. Dermatol. Venereol. Leprol. 2013; 79: 529-213. FI: 1.206 (Q3).

HLA Associations Distinguish Collagenous From Lymphocytic Colitis.

Westerlind H, Bonfiglio F, Mellander MR, Huebenthal M, Brynedal B, Bjork J, Torkvist L, Padyukov L, Ohlsson B, Lofberg R, Hultcrantz R, Franke A, Bresso F, D'Amato M.

American Journal Of Gastroenterology. 2016; 111: 1211-1213. FI: 9,566 (Q1).


Published: 1 / 1

Hospital variation in anastomotic leakage after rectal cancer surgery in the Spanish Association of Surgeons project: The contribution of hospital volume.

Ortiz H, Biondo S, Codina A, Ciga MÁ, Enríquez-Navascués J, Espín E, García-Granero E, Roig JV.

Cirugia Española. 2016; 94: 213-220. FI: 1,276 (Q3).


Projects 3 / 3

Effects of Piceatannol on obesity complications. Polyfresnol.

Investigador Principal: Elizabeth Hijona Muruamendiaraz. Entidad Financiadora: POCTEFA-Interreg IV A. Año inicio: 2013. Año final: 2015.

Papel de los exosomas en el desarrollo y patogenia de la enfermedad inflamatoria intestinal y la colangitis.

Investigador Principal: Luis Bujanda Fernández de Piérola. Entidad Financiadora: Diputación Foral de Gipuzkoa. Año inicio: 2014. Año final: 2015.

Papel de las vesículas extracelulares en la tumorogénesis del epitelio biliar y en el desarrollo de la enfermedad inflamatoria intestinal.

Investigador Principal: Luis Bujanda Fernández de Piérola. Entidad Financiadora: Gobierno Vasco, Departamento de Salud. Año inicio: 2013. Año final: 2016.